Improved Drug Adherence in Patients with Chronic Myeloid Leukemia in the Chronic Phase by Switching to Second-Generation Tyrosine Kinase Inhibitors

Maeda, Yasuhiro; Okamoto, Atsushi; Kawaguchi, Shinichiro; Konishi, Akiko; Yamamoto, Kenta; Eguchi, Go; Kanai, Yoshitaka; Yamaguchi, Tadatoshi

doi:10.1159/000477893

Cited by 3 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the QoL score was significantly decreased in most patients who switched to NILO, which might be the result of fewer ADEs. Previously, we reported that statistically significant differences in adherence, defined by an MMAS score of (p = 0.0011), were observed between the IM and NILO groups [18]. It has been reported that adherence is the most critical factor for achieving clinical response and ultimately for improving survival in patients with CML receiving TKI therapy [4,14].…”

Section: Discussionmentioning

confidence: 86%

Clinical Importance of Drug Adherence during Tyrosine Kinase Inhibitor Therapy for Chronic Myelogenous Leukemia in Chronic Phase

Maeda¹,

Okamoto²,

Yamamoto³

et al. 2019

Preprint

Self Cite

View full text Add to dashboard Cite

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm constituting approximately 15% of newly diagnosed leukemia in adult patients. Development of tyrosine kinase inhibitors (TKIs) have dramatically improved outcomes in patients with chronic CML in chronic phase. However, adverse drug events (ADEs) associated with TKI therapy have influenced drug adherence, resulting in adverse clinical outcomes and a decline in the quality of life (QoL). In this study, we carried out a unique questionnaire survey to evaluate ADEs, which comprised 14 adverse events. We compared drug adherence rates between patients using imatinib and those who switched from imatinib to nilotinib, a second-generation TKI. Following the switch, the total number of ADEs decreased considerably in most cases. Simultaneously, better QoL was observed in the nilotinib group than in the imatinib group. Drug adherence was measured using Morisky’s 9-item Medication Adherence Scale (MMAS). MMAS increased significantly after switching to nilotinib in all cases. Drug adherence is a critical factor for achieving molecular response in patients with CML. In fact, our results showed a strong inverse correlation between clinical outcome [international scale (IS)] and adherence (MMAS), with a stronger tendency in the nilotinib group than in the imatinib group. In conclusion, low occurrence of ADEs induced a high level of QoL and a good clinical response with second-generation TKI nilotinib treatment.

show abstract

Section: Discussionmentioning

confidence: 86%

Clinical Importance of Drug Adherence during Tyrosine Kinase Inhibitor Therapy for Chronic Myelogenous Leukemia in Chronic Phase

Maeda¹,

Okamoto²,

Yamamoto³

et al. 2019

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…In our study, the QoL score was significantly decreased in most patients who switched to NILO, which might be the result of fewer ADEs. Previously, we reported that statistically significant differences in adherence, defined by an MMAS score of (p = 0.0011), were observed between the IM and NILO groups [19]. It has been reported that adherence is the most critical factor for achieving clinical response and ultimately for improving survival in patients with CML receiving TKI therapy [4,14].…”

Section: Discussionmentioning

confidence: 86%

Clinical Importance of Drug Adherence during Tyrosine Kinase Inhibitor Therapy for Chronic Myelogenous Leukemia in Chronic Phase

Maeda

Okamoto

Yamamoto

et al. 2019

Reports

Self Cite

View full text Add to dashboard Cite

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm constituting approximately 15% of newly diagnosed leukemia in adult patients. Development of tyrosine kinase inhibitors (TKIs) have dramatically improved outcomes in patients with chronic CML in chronic phase. However, adverse drug events (ADEs) associated with TKI therapy have influenced drug adherence, resulting in adverse clinical outcomes and a decline in the quality of life (QoL). In this study, we carried out a unique questionnaire survey to evaluate ADEs, which comprised 14 adverse events. We compared drug adherence rates between patients using imatinib and those who switched from imatinib to nilotinib, a second-generation TKI. Following the switch, the total number of ADEs decreased considerably in most cases. Simultaneously, better QoL was observed in the nilotinib group than in the imatinib group. Drug adherence was measured using Morisky’s 9-item Medication Adherence Scale (MMAS). MMAS increased significantly after switching to nilotinib in all cases. Drug adherence is a critical factor for achieving molecular response in patients with CML. In fact, our results showed a strong inverse correlation between clinical outcome (international scale (IS)) and adherence (MMAS), with a stronger tendency in the nilotinib group than in the imatinib group. In conclusion, low occurrence of ADEs induced a high level of QoL and a good clinical response with second-generation TKI nilotinib treatment.

show abstract

“…The retrospective study conducted by Maeda et al [6], published in this issue of Acta Haematologica , provides hypothesis-generating data suggesting that switching the TKI medication may be a possible solution to unintentional nonadherence in certain scenarios. The study compares adherence between patients treated with imatinib and those switched from imatinib to nilotinib, in a small cohort of 20 CML patients in Japan.…”

mentioning

confidence: 99%

Switching-On Adherence in Chronic Myeloid Leukemia

Leader

Raanani²

2017

Acta Haematol

View full text Add to dashboard Cite

Improved Drug Adherence in Patients with Chronic Myeloid Leukemia in the Chronic Phase by Switching to Second-Generation Tyrosine Kinase Inhibitors

Cited by 3 publications

References 17 publications

Clinical Importance of Drug Adherence during Tyrosine Kinase Inhibitor Therapy for Chronic Myelogenous Leukemia in Chronic Phase

Clinical Importance of Drug Adherence during Tyrosine Kinase Inhibitor Therapy for Chronic Myelogenous Leukemia in Chronic Phase

Clinical Importance of Drug Adherence during Tyrosine Kinase Inhibitor Therapy for Chronic Myelogenous Leukemia in Chronic Phase

Switching-On Adherence in Chronic Myeloid Leukemia

Contact Info

Product

Resources

About